Findings from the phase II ASSET trial suggest that patients with diffuse cutaneous systemic sclerosis who are treated with abatacept do not experience significantly greater improvements in skin disease than those given placebo.
The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.
Cutaneous adverse reactions resulting from programmed cell death protein 1 inhibitor therapy can occur late after treatment initiation or even after discontinuation, according to findings reported in JAMA Dermatology.
Patients with metastatic melanoma who achieve a complete response with pembrolizumab therapy have a low risk for disease progression or death, report researchers who believe that treatment discontinuation is possible in this setting.
The expression of the histone methyltransferase EZH2 correlates with aggressive subtypes of cutaneous basal cell carcinoma, highlighting the possibility that EZH2 may be an actionable target in this malignancy, say researchers.
In solid-organ transplant recipients (OTRs) diagnosed with cancer post-transplant, treatment with sirolimus reduces the risk of developing a subsequent skin cancer, US investigators report in JAMA Dermatology.
There is significant discordance between the results of allergen-specific skin prick tests and allergen-specific serum immunoglobulin E levels for identifying aeroallergen sensitization in children under the age of 4 years, a study finds.